Skip to main content
. Author manuscript; available in PMC: 2018 Jul 15.
Published in final edited form as: Clin Cancer Res. 2017 Feb 6;23(14):3711–3720. doi: 10.1158/1078-0432.CCR-16-3215

Figure 1. PARPi upregulates PD-L1 protein expression in breast cancer cells.

Figure 1

(A) MDA-MDA-MB-231 and BT549 cells were treated with 10 μM olaparib or 10 nM talazoparib for 24 hours, and subjected to immunoblotting with the indicated antibodies. PD-L1 knockout (K/O) cells were included as a negative control. (B) PD-L1 expression in PARP1 knockdown (K/D), PARP1 knockout (K/O), and MDA-MB-231 parental cells by immunoblotting. (C and D) The indicated MDA-MB-231 cells were subjected to FACS analysis for cell surface PD-L1 expression. (E) SUM149 cells were treated with the indicated concentrations of olaparib for 10 days, and cell surface PD-L1 expression was determined by FACS.